Microbot Medical Inc. (NASDAQ:MBOT – Free Report) – Stock analysts at HC Wainwright decreased their FY2027 earnings per share estimates for shares of Microbot Medical in a research note issued to investors on Wednesday, October 21st. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings per share of ($0.29) for the year, down from their prior forecast of ($0.28). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.30) per share.
Several other equities research analysts also recently issued reports on the stock. Citigroup began coverage on shares of Microbot Medical in a research note on Friday. They set a “market outperform” rating for the company. Zacks Research downgraded shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a report on Friday, October 2nd. UBS Group set a $2.50 price target on shares of Microbot Medical in a research report on Friday. Finally, Citizens Jmp started coverage on Microbot Medical in a report on Friday. They issued an “outperform” rating and a $2.50 price target for the company. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $5.08.
Read Our Latest Analysis on Microbot Medical
Microbot Medical Stock Performance
NASDAQ MBOT opened at $0.94 on Friday. Microbot Medical has a one year low of $0.93 and a one year high of $2.85. The company’s 50 day moving average price is $1.30 and its 200 day moving average price is $1.72. The firm has a market capitalization of $63.27 million, a price-to-earnings ratio of -3.92 and a beta of 1.05.
Microbot Medical (NASDAQ:MBOT – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. CTC Alternative Strategies Ltd. purchased a new position in shares of Microbot Medical in the first quarter valued at $28,000. Cetera Investment Advisers lifted its holdings in Microbot Medical by 44.7% in the 1st quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock worth $102,000 after buying an additional 13,099 shares in the last quarter. Private Advisor Group LLC purchased a new position in Microbot Medical in the 1st quarter valued at about $54,000. Caitong International Asset Management Co. Ltd purchased a new position in Microbot Medical in the 4th quarter valued at about $65,000. Finally, Bank of America Corp DE grew its stake in shares of Microbot Medical by 1,688.1% during the first quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 71,560 shares in the last quarter. 16.30% of the stock is owned by institutional investors and hedge funds.
Microbot Medical Company Profile
Microbot Medical Inc (NASDAQ: MBOT) is a medical device company developing robotic and computer-assisted technologies for minimally invasive endovascular procedures. The company focuses on systems intended to help physicians navigate blood vessels and deliver interventional devices while potentially improving procedural control and reducing radiation exposure to medical personnel.
Microbot Medical’s primary product candidate is the LIBERTY Endovascular Robotic System, a single-use, disposable robotic platform designed to remotely control guidewires and catheters during vascular procedures.
Read More
- Five stocks we like better than Microbot Medical
- Microsoft’s Earnings Problem: Even Great May Not Be Enough
- 3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
